Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

3(50.0%)

6Total

N/A(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04569214Phase 2Withdrawn

The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients

Role: lead

NCT03655535Phase 2Completed

Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

Role: lead

NCT02135549Not ApplicableCompleted

Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin

Role: lead

NCT03375398Not ApplicableCompleted

Determination of the PPG and Insulin Responses of Rice Alone and Rice Consumed With Sugardown™

Role: lead

NCT03374501Not ApplicableCompleted

Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™

Role: lead

NCT02060916Phase 2Completed

Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

Role: lead

All 6 trials loaded